Janus Henderson Group PLC reduced its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 98.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,047 shares of the biotechnology company's stock after selling 1,008,511 shares during the period. Janus Henderson Group PLC's holdings in Prothena were worth $301,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. DCF Advisers LLC increased its stake in Prothena by 0.5% during the 2nd quarter. DCF Advisers LLC now owns 107,500 shares of the biotechnology company's stock valued at $2,219,000 after purchasing an additional 500 shares in the last quarter. Signaturefd LLC increased its stake in Prothena by 182.1% during the 2nd quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 863 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Prothena by 13.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company's stock valued at $211,000 after purchasing an additional 1,186 shares in the last quarter. Pinnacle Associates Ltd. increased its stake in Prothena by 2.3% during the 3rd quarter. Pinnacle Associates Ltd. now owns 125,747 shares of the biotechnology company's stock valued at $2,104,000 after purchasing an additional 2,847 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Prothena by 3.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company's stock valued at $1,440,000 after purchasing an additional 3,163 shares in the last quarter. 97.08% of the stock is owned by hedge funds and other institutional investors.
Prothena Trading Down 1.4 %
PRTA traded down $0.18 during trading hours on Monday, hitting $12.61. The company's stock had a trading volume of 603,029 shares, compared to its average volume of 574,253. The business's 50-day moving average price is $15.89 and its 200-day moving average price is $19.26. Prothena Co. plc has a 12 month low of $12.44 and a 12 month high of $41.54. The stock has a market cap of $678.53 million, a price-to-earnings ratio of -5.08 and a beta of 0.09.
Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, beating analysts' consensus estimates of ($1.18) by $0.08. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The business had revenue of $0.97 million for the quarter, compared to analysts' expectations of $1.22 million. During the same quarter in the previous year, the business posted $0.38 earnings per share. The business's revenue was down 98.9% compared to the same quarter last year. On average, analysts forecast that Prothena Co. plc will post -2.24 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research firms have weighed in on PRTA. Bank of America reduced their price objective on shares of Prothena from $33.00 to $31.00 and set a "neutral" rating for the company in a research note on Tuesday, October 1st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Prothena in a research note on Monday, September 30th. StockNews.com lowered shares of Prothena from a "hold" rating to a "sell" rating in a research report on Tuesday, November 19th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $84.00 price target on shares of Prothena in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Prothena currently has an average rating of "Hold" and a consensus target price of $61.83.
View Our Latest Analysis on Prothena
Prothena Company Profile
(
Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Articles
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
